UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): June 6, 2023

GoHealth, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39390	85-0563805
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
214 West Huron St.		
Chicago, Illinois		60654
(Address of principal executive offices)		(Zip Code)
	(312) 386-8200	
(Regist	trant's telephone number, including area coc	le)
	N/A	
(Former na	me or former address, if changed since last	report)
Check the appropriate box below if the Form 8-K filing is in provisions:	, , ,	ligation of the registrant under any of the following
	r the Securities Act (17 CFR 230.425). le Exchange Act (17 CFR 240.14a-12). cule 14d-2(b) under the Exchange Act (17 Cl	FR 240.14d-2(b)).
orovisions: Written communications pursuant to Rule 425 unde Soliciting material pursuant to Rule 14a-12 under the Pre-commencement communications pursuant to Rule Pre-commencement communications pursuant to Rule	r the Securities Act (17 CFR 230.425). le Exchange Act (17 CFR 240.14a-12). cule 14d-2(b) under the Exchange Act (17 Cl	FR 240.14d-2(b)).
provisions: Written communications pursuant to Rule 425 unde Soliciting material pursuant to Rule 14a-12 under the Pre-commencement communications pursuant to Rule Pre-commencement communications pursuant to Rule	r the Securities Act (17 CFR 230.425). le Exchange Act (17 CFR 240.14a-12). cule 14d-2(b) under the Exchange Act (17 Cl	FR 240.14d-2(b)).
provisions: Written communications pursuant to Rule 425 unde Soliciting material pursuant to Rule 14a-12 under th Pre-commencement communications pursuant to R Pre-commencement communications pursuant to R Securities registered pursuant to Section 12(b) of the Act:	or the Securities Act (17 CFR 230.425). Die Exchange Act (17 CFR 240.14a-12). Eule 14d-2(b) under the Exchange Act (17 Clude 13e-4(c) under the Exchange A	FR 240.14d-2(b)). FR 240.13e-4(c)). Name of each exchange
orovisions: ☐ Written communications pursuant to Rule 425 under ☐ Soliciting material pursuant to Rule 14a-12 under the ☐ Pre-commencement communications pursuant to Roman Pre-commencement communications pursuant to Recurities registered pursuant to Section 12(b) of the Act: Title of each class Class A Common Stock,	r the Securities Act (17 CFR 230.425). le Exchange Act (17 CFR 240.14a-12). lule 14d-2(b) under the Exchange Act (17 Clule 13e-4(c) under the Exchange Act (FR 240.14d-2(b)). FR 240.13e-4(c)). Name of each exchange on which registered The Nasdaq Global Market
orovisions: ☐ Written communications pursuant to Rule 425 under ☐ Soliciting material pursuant to Rule 14a-12 under the ☐ Pre-commencement communications pursuant to Roman Pre-commencement communications pursuant to Recurities registered pursuant to Section 12(b) of the Act: Title of each class Class A Common Stock, \$0.0001 par value per share	r the Securities Act (17 CFR 230.425). le Exchange Act (17 CFR 240.14a-12). lule 14d-2(b) under the Exchange Act (17 Clule 13e-4(c) under the Exchange Act (FR 240.14d-2(b)). FR 240.13e-4(c)). Name of each exchange on which registered The Nasdaq Global Market

Item 5.02(b). Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 6, 2023, GoHealth, Inc. (the "Company") announced the departure of Shane Cruz, the current Chief Strategy Officer, whose employment will terminate as of June 30, 2023. Mr. Cruz has served in various leadership roles at the Company for nearly 20 years and the Company is grateful for his service.

The separation of employment will be pursuant to Mr. Cruz's current Amended & Restated Employment Agreement dated as of August 1, 2022 (the "Employment Agreement"). Pursuant to the Employment Agreement, Mr. Cruz is entitled to (i) a continuation of base salary for a two (2) year period, (ii) a cash bonus for 2023 at 100% of the targeted bonus (provided, however, that if there is a change of control within 12 months of separation, such bonus shall be multiplied by two), (iii) acceleration of any unvested LLC profits interests granted to Mr. Cruz prior to the 2020 initial public offering, (iv) acceleration of any unvested equity awards issued by the Company that would have vested within the 24 month period beginning on the separation date had Mr. Cruz remained employed by the Company, and (v) up to 24 months of COBRA premium reimbursement. The separation benefits under the Employment Agreement are subject to the Mr. Cruz's execution and non-revocation of a release of claims in favor of the Company and continued compliance with applicable restrictive covenants.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GOHEALTH, INC.

Date: June 6, 2023

By: /s/ Brian Farley

Brian Farley Chief Legal Officer